Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2022-06-01 Major Shareholding Noti…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Galapagos receives transparency notification from FMR LLC .pdf
Major Shareholding Notification Classification · 98% confidence The document is a short announcement dated June 1, 2022, stating that Galapagos NV received a transparency notification from FMR LLC. The content details that FMR LLC crossed the 5% threshold of voting rights due to the acquisition of voting securities on May 27, 2022. This type of notification, reporting changes in significant share ownership that cross regulatory thresholds (like 5%), directly corresponds to the definition of a Major Shareholding Notification. The code for this is MRQ.
2022-06-01 English
Galapagos ontvangt transparantieverklaring van FMR LLC.pdf
Major Shareholding Notification Classification · 98% confidence The document is a formal announcement from Galapagos NV, dated June 1, 2022, stating that it received a 'kennisgeving van belangrijke deelneming' (notification of significant shareholding) from FMR LLC. The text explicitly details the number of voting rights (5.04%) crossing the 5% notification threshold due to securities acquired on May 27, 2022, referencing Belgian transparency legislation. This content directly corresponds to the definition of a Major Shareholding Notification, which involves reporting changes in significant share ownership levels crossing specific thresholds.
2022-06-01 Dutch
6-K Filing
Regulatory Filings
2022-05-31 English
Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress
Regulatory Filings Classification · 95% confidence The document is a press release dated May 25, 2022, announcing that Galapagos NV will present 11 abstracts at the European League Against Rheumatism (EULAR) congress 2022. It details the topics, including trial data analyses for filgotinib, and mentions hosted symposiums and meet-the-expert sessions. This content is typical of a company communicating its scientific research and participation in a major medical/industry conference. It is not a formal regulatory filing (like 10-K, IR, or ER), nor is it a general announcement of a report publication (RPA). It is best classified as Investor Presentation (IP) material, as it details scientific findings and strategy presentations intended for investors and the medical community, even though it's delivered via a press release format detailing conference participation.
2022-05-26 English
Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress
Regulatory Filings Classification · 95% confidence The document is an announcement from Galapagos NV detailing their participation in the European League Against Rheumatism (EULAR) congress 2022. It specifies the number of abstracts (11) to be presented, the topics (focusing on filgotinib for rheumatoid arthritis), and mentions organized symposia and expert sessions. This content is characteristic of scientific updates and presentations shared with the investment and medical community regarding ongoing research and clinical data dissemination, which aligns best with an Investor Presentation (IP) or a general scientific/research update. Since it is an announcement about presenting research data at a major conference, 'Investor Presentation' (IP) is the most fitting category, as these presentations often form the basis of investor briefings on R&D progress. It is not a formal regulatory filing (like 10-K or IR), nor is it a general earnings release (ER) or a transcript (CT).
2022-05-26 English
EGM & AGM minutes (ENG)(511592.1) (1)_2022.pdf
AGM Information Classification · 99% confidence The document details the proceedings of an 'EXTRAORDINARY AND ORDINARY SHAREHOLDERS' MEETINGS' for GALAPAGOS. The key agenda items involve 'Amendments to articles of association as a consequence of the choice for a one-tier board structure' and the 'Appointment of the members of the board of directors'. This content—minutes or official record of decisions made at a general meeting of shareholders, including voting on structural changes and director appointments—is characteristic of the formal documentation associated with an Annual General Meeting (AGM). Since the document appears to be the official record/minutes of the meeting itself, and not just a presentation (IP) or a proxy solicitation (PSI), the most appropriate classification is AGM-R (AGM Information/Record).
2022-05-11 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.